Page 37 - GTM-4-2

Global Translational Medicine Small RNA therapy for pancreatic cancer

Guyer DR. Pegaptanib for neovascular age-related macular 85. Frampton JE. Inclisiran: A review in hypercholesterolemia.
degeneration. N Engl J Med. 2004;351(27):2805-2816. Am J Cardiovasc Drugs. 2023;23(2):219-230.
doi: 10.1056/NEJMoa042760 doi: 10.1007/s40256-023-00568-7
72. Gryziewicz L. Regulatory aspects of drug approval for macular 86. Lamb YN. Inclisiran: First approval. Drugs. 2021;81(3):389-395.
degeneration. Adv Drug Deliv Rev. 2005;57(14):2092-2098.
doi: 10.1007/s40265-021-01473-6
doi: 10.1016/j.addr.2005.09.009
87. Fitzgerald K, White S, Borodovsky A, et al. A highly durable
73. Morrow T. For patients who inherit homozygous familial RNAi therapeutic inhibitor of PCSK9. N Engl J Med.
hypercholesterolemia, 2 new treatments available. Manag 2017;376(1):41-51.
Care. 2013;22(3):47-48. doi: 10.1056/NEJMoa1609243
74. Stein CA. Eteplirsen approved for duchenne muscular 88. Simoens S, Huys I. Market access of Spinraza (Nusinersen)
dystrophy: The FDA faces a difficult choice. Mol Ther. for spinal muscular atrophy: Intellectual property rights,
2016;24(11):1884-1885.
pricing, value and coverage considerations. Gene Ther.
doi: 10.1038/mt.2016.188 2017;24(9):539-541.
75. Syed YY. Eteplirsen: First global approval. Drugs. doi: 10.1038/gt.2017.79
2016;76(17):1699-1704. 89. Burgart AM, Magnus D, Tabor HK, et al. Ethical challenges
doi: 10.1007/s40265-016-0657-1 confronted when providing nusinersen treatment for spinal
muscular atrophy. JAMA Pediatr. 2018;172(2):188-192.
76. Ottesen EW. ISS-N1 makes the first FDA-approved drug for
spinal muscular atrophy. Transl Neurosci. 2017;8:1-6. doi: 10.1001/jamapediatrics.2017.4409
doi: 10.1515/tnsci-2017-0001 90. Ho PY, Yu AM. Bioengineering of noncoding RNAs for
research agents and therapeutics. Wiley Interdiscip Rev RNA.
77. Keam SJ. Inotersen: First global approval. Drugs.
2018;78(13):1371-1376. 2016;7(2):186-197.
doi: 10.1002/wrna.1324
doi: 10.1007/s40265-018-0968-5
91. Yu AM, Batra N, Tu MJ, Sweeney C. Novel approaches for
78. Saad FA, Siciliano G, Angelini C. Advances in efficient in vivo fermentation production of noncoding
dystrophinopathy diagnosis and therapy. Biomolecules. RNAs. Appl Microbiol Biotechnol. 2020;104(5):1927-1937.
2023;13(9):1319.
doi: 10.1007/s00253-020-10350-3
doi: 10.3390/biom13091319
92. Bramsen JB, Kjems J. Development of therapeutic-grade
79. Chen W, Xu J, Wu Y, et al. The potential role and mechanism
of circRNA/miRNA axis in cholesterol synthesis. Int J Biol small interfering RNAs by chemical engineering. Front
Genet. 2012;3:154.
Sci. 2023;19(9):2879-2896.
doi: 10.3389/fgene.2012.00154
doi: 10.7150/ijbs.84994
93. Khvorova A, Watts JK. The chemical evolution of
80. Wood H. FDA approves patisiran to treat hereditary oligonucleotide therapies of clinical utility. Nat Biotechnol.
transthyretin amyloidosis. Nat Rev Neurol. 2018;14(10):570.
2017;35(3):238-248.
doi: 10.1038/s41582-018-0065-0
doi: 10.1038/nbt.3765
81. Scott LJ. Givosiran: First approval. Drugs. 2020;80(3): 94. Yu AM, Jian C, Yu AH, Tu MJ. RNA therapy: Are we using
335-339.
the right molecules? Pharmacol Ther. 2019;196:91-104.
doi: 10.1007/s40265-020-01269-0
doi: 10.1016/j.pharmthera.2018.11.011
82. Gang X, Liu F, Mao J. Lumasiran for primary hyperoxaluria 95. Wan WB, Seth PP. The medicinal chemistry of therapeutic
type 1: What we have learned? Front Pediatr. 2022;10:1052625.
oligonucleotides. J Med Chem. 2016;59(21):9645-9667.
doi: 10.3389/fped.2022.1052625
doi: 10.1021/acs.jmedchem.6b00551
83. Keam SJ. vutrisiran: First approval. Drugs. 2022;82(13):1419- 96. Eckstein F. Phosphorothioates, essential components
1425.
of therapeutic oligonucleotides. Nucleic Acid Ther.
doi: 10.1007/s40265-022-01765-5 2014;24(6):374-387.
84. Perry CM, Balfour JA. Fomivirsen. Drugs. 1999;57(3):375- doi: 10.1089/nat.2014.0506
380; discussion 381.
97. Setten RL, Rossi JJ, Han SP. The current state and future
doi: 10.2165/00003495-199957030-00010 directions of RNAi-based therapeutics. Nat Rev Drug

Volume 4 Issue 2 (2025) 29 doi: 10.36922/gtm.8247